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Objective: Brugada syndrome (BrS) is characterized by ventricular tachyarrhythmias leading to sudden cardiac death and is caused, in part,
by mutations in the SCN5A gene encoding the sodium channel Nav1.5. Fever can trigger or exacerbate the clinical manifestations of BrS. The
aim of this work was to characterize the genetic and molecular determinants of fever-dependent BrS.
Methods: Four male patients with typical BrS ST-segment elevation in V1–V3 or ventricular arrhythmias during fever were screened for
mutations in the SCN5A gene. Wild-type (WT) and mutant Nav1.5 channels were expressed in HEK293 cells. The sodium currents (INa) were
analysed using the whole-cell patch clamp technique at various temperatures. Protein expression of WT and mutant channels was studied by
Western blot experiments.
Results: Two mutations in SCN5A, L325R and R535X, were identified. Expression of the two mutant Nav1.5 channels in HEK293 cells
revealed in each case a severe loss-of-function. Upon the increase of temperature up to 42 -C, we observed a pronounced acceleration of
Nav1.5 activation and fast inactivation kinetics. Cardiac action potential modelling experiments suggest that in patients with reduced INa,
fever could prematurely shorten the action potential by virtue of its effect on WT channels. Further experiments revealed that L325R channels
are likely misfolded, since their function could be partially rescued by mexiletine or curcumin. In co-expression experiments, L325R
channels interfered with the proper function of WT channels, suggesting that a dominant negative phenomenon may underlie BrS triggered
by fever.
Conclusions: The genetic background of BrS patients sensitive to fever is heterogeneous. Our experimental data suggest that the clinical
manifestations of fever-exacerbated BrS may not be mutation specific.
D 2005 European Society of Cardiology. Published by Elsevier B.V. All rights reserved.Keywords: Arrhythmia (mechanism); Na-channel; Sudden death0008-6363/$ - s
doi:10.1016/j.ca
* Correspondi
Bugnon, 27, 100
1011 Lausanne,
E-mail addr
1 Both authors67 (2005) 510 – 519ee front matter D 2005 European Society of Cardiology. Published by Elsevier B.V. All rights reserved.
rdiores.2005.03.024
ng authors. H. Abriel is to be contacted at Service of Cardiology, and Department of Pharmacology and Toxicology, University of Lausanne,
5 Lausanne, Switzerland. Tel.: +41 21 6925364; fax: +41 21 6935355. J. Schla¨pfer, Service of Cardiology, CHUVand University of Lausanne,
Switzerland. Tel.: +41 21 3140052; fax: +41 21 3140013.
esses: Jurg.Schlaepfer@chuv.hospvd.ch (J. Schla¨pfer), Hugues.Abriel@unil.ch (H. Abriel).
contributed equally to this study.
D.I. Keller et al. / Cardiovascular Research 67 (2005) 510–519 5111. Introduction
Brugada syndrome (BrS) is characterized by ST segment
elevation in the right precordial leads V1–V3 on the surface
ECG, with incomplete or complete right bundle branch
block and an increased risk for sudden cardiac death (SCD)
caused by polymorphic ventricular tachycardia or fibrilla-
tion (VT/VF) [1]. The BrS is a primary electrical cardiac
disorder with no apparent underlying structural heart disease
and is inherited by an autosomal dominant trait. Mutations
have been identified in the SCN5A gene encoding the a-
subunit of the voltage-gated sodium channel Nav1.5 [2].
Yet, only 10–30% of clinically affected individuals carry a
mutation in this gene [3]. Most of SCN5A mutations lead to
a ‘‘loss-of-function’’ by reducing the sodium current (INa)
available during the phases 0 (upstroke) and 1 (early
repolarization) of the cardiac action potential (AP) [1].
The molecular and cellular mechanisms leading to the
BrS are not yet completely understood. In some patients, the
BrS is concealed on the surface ECG and can be unmasked
using sodium channel blockers. Furthermore, fever has been
reported to unmask or exacerbate the typical BrS ECG
pattern on the surface ECG and to trigger VT [4]. During the
past six years, several case reports of fever-induced BrS
have been published [5–9].
In the present study, we screened SCN5A in four
unrelated patients presenting typical BrS ECGs during
episodes of fever. Two heterozygous mutations were
identified: a novel missense mutation, L325R, and a non-
sense mutation, R535X. We carried out molecular and
functional analyses of the consequences of these two
mutations, using classical biochemical and patch-clamp
techniques. The two mutations markedly decreased the INa
after transfection of the mutant proteins, suggesting that
reduced availability of INa during the early phase of the
cardiac AP may cause fever-induced tachyarrhythmias. We
also provide experimental evidence for protein misfolding
resulting from the L325R mutation, since the INa mediated
by these mutant channels was partially rescued by curcumin
and mexiletine. In addition, we present data suggesting for
the first time that BrS mutant channels may exert a
dominant negative effect on WT channels.2. Methods
This study was performed according to the guidelines of
the Swiss Society of Medical Genetics and conforms to the
Declaration of Helsinki. All individuals gave written
informed consent to participate in the study.
2.1. Molecular screening
Genomic DNA was extracted from peripheral lympho-
cytes. In the four patients, the coding exons of SCN5A were
amplified by polymerase chain reaction (PCR), usingprimers designed in intronic flanking sequences, according
to the gene sequences [10]. Denaturating high performance
liquid chromatography (DHPLC) was performed on DNA-
amplification products in at least one temperature condition.
Abnormal DHPLC profiles were analysed by sequence
reaction in both strands of the exon, using big dye
termination mix, and analysed by cycle sequencing on an
automated laser fluorescent DNA sequencer (ABI prism
3100, Applied Biosystems). The novel mutation L325R was
absent in 200 normal alleles.
2.2. Functional and biochemical analysis of Na+ channels
SCN5A mutations were engineered into WT cDNA
(clone hH1a received from Dr. R. Kass) cloned in
pcDNA3.1 (Invitrogen), using the QuickChange Kit (Stra-
tagene) and verified by sequencing. For electrophysiology
studies, HEK293 cells were transiently transfected with 0.6
Ag WT or mutant Nav1.5 construct cDNAs or as indicated.
All transfections included 2.0 Ag pIRES-hh1-CD8 cDNA
encoding hh1 subunit and CD8 antigen, as a reporter gene.
Cells were transfected using calcium phosphate and INa
were measured after 48 h. Anti-CD8 beads (Dynal) were
used to identify transfected cells. Patch-clamp recordings
were carried-out using an internal solution containing
(mmol/L) CsCl 60; Cs Aspartate 70; EGTA 11; MgCl2 1;
CaCl2 1; HEPES 10; and Na2-ATP 5, pH 7.2 with CsOH;
external solution NaCl 130; CaCl2 2; MgCl2 1.2; CsCl 5;
HEPES 10; and glucose 5, pH 7.4 with CsOH. Using these
solutions, 5 min after rupturing the membrane, we observed
no significant alteration of the availability curve and the
peak current. Holding potentials were 100 mVand no leak
subtraction was performed. Peak currents were measured
during a current-voltage protocol and INa densities (pA/pF)
were obtained by dividing the peak INa by the cell
capacitance obtained from the pClamp function. Measure-
ments were carried out at different temperatures using a
control system (Cell MicroControls) heating the perfusion
solution. Obtaining an adequate voltage-clamp control when
measuring voltage-gated INa in voltage-clamp conditions at
physiological temperatures may represent a difficult task.
We took great care to ensure the best possible voltage-clamp
control: (1) We compensated the series resistances by
virtually 100% using a VE-2 amplifier (Alembic Instru-
ments) based on a ‘‘state estimator’’ series resistance
compensation approach [11]. (2) The resistance of the
pipettes was in the range of 1.7–2.5 MV. (3) We used data
only from cells where the access resistance remained stable
over all the duration of the experiment. (4) Cells for which
signs of poor voltage-clamp control such as delayed
inflections of the current or discontinuities in the peak INa
vs. Vm curve were not analysed. As presented in the Table
1, despite the fact that activation kinetics were faster with
increasing temperature (22 -C up to 42 -C, see Fig. 4) the
voltage dependence of activation characterized by the V1/2
of activation and, most importantly, the slope factor K were
Table 1
The following biophysical parameters of WT and L325R channels were recorded at 22, 37 and 42 -C: V1 / 2 values and slope factor (K) of the voltage-
dependence of steady-state activation and inactivation
22 -C 37 -C 42 -C
Activation
K (mV/e-fold) WT 5.4T0.4 (n =9) 4.9T0.4 (n =6) 5.3T 0.2 (n =5)
L325R 7.2T0.3 (n =7) * 7.9T0.3 (n =4) * 8.4T1.0 (n =4) *
V1 / 2 (mV) WT 41.0T2.3 (n =9) 42.8T1.7 (n =6) 42.0T2.3 (n =5)
L325R 31.0T1.1 (n =7) ** 32.4T3.5 (n =4) * 33.3T1.7 (n =4) *
Time to the peak (ms) WT 0.49T0.03 (n =9) 0.35T0.06 (n =5) # 0.36T0.07 (n = 5) #
L325R 0.71T0.03 (n =7) *** 0.47T0.02 (n =4) n.s. ### 0.43T0.04 (n =4) n.s. ###
Inactivation
K (mV/e-fold) WT 6.1T0.3 (n =5) 5.8T0.4 (n =5) 5.5T0.3 (n =5)
L325R 5.9T0.2 (n =18) n.s. 4.9T0.3 (n = 9) n.s. 5.5T0.7 (n =8) n.s.
V1/2 (mV) WT 77.1T1.6 (n =5) 77.7T1.9 (n =5) 77.9T2.3 (n =5)
L325R 74.0T1.0 (n =18) n.s. 73.3T1.6 (n =12) n.s. 71.3T0.9 (n =8) **
s (ms) WT 0.52T0.02 (n =7) 0.29T0.02 (n = 3) ### 0.25T0.02 (n =3) ###
L325R 0.84T0.05 (n =7) *** 0.58T0.05 (n =4) ** ## 0.60T0.04 (n =4) ** #
INa amplitude (%) WT 100T19 (n = 11) 118T3 (n =9) ### 116T4 (n =6) ##
L325R 100T10 (n =14) 119T4 (n =8) ### 124T8 (n =5) ##
Steady-state inactivation protocol used: 25-ms test pulse to 20 mV after a 500-ms conditioning pulse. The data from individual cells were fitted with
Boltzmann relationship, y(Vm)=1/ (1+exp[(VmV1 / 2) /K]), in which y is the normalized current or conductance, Vm is the membrane potential, V1 / 2 is the
voltage at which half of the channels are activated or inactivated, and K is the slope factor.
Mean time to the peak INa, time constant (s) of onset of fast inactivation, and normalized peak INa were all measured at 20 mV, number of cells in
parenthesis; *, **, ***p <0.05, 0.01, 0.001 vs. WT; #, ##, ### p <0.05, 0.01, 0.001 vs. 22 -C respectively; n.s. not significant vs. WT.
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that the quality of the voltage-clamp control was comparable
at all temperatures tested. In some experiments, cells were
pre-incubated with thapsigargin (Acros), curcumin (Acros),
or mexiletine (Sigma). The cells were washed of the drugs
10 min prior to the recordings.
Western blotting conditions have been described pre-
viously [12]. The anti-Nav1.5 affinity purified antibody
recognizes residues 493–511 of rat Nav1.5 (ASC-005,
Alomone). These residues are identical in the human
sequence. Anti-actin antibody was from Sigma.
Data are presented as meansTSEM. Two-tailed Student t-
test was used to compare means; p <0.05 was considered
significant.
2.3. Mathematical modelling of INa and of the action
potential
WT INa was modelled using the 6-state Markovian model
of Clancy and Rudy [13] (errata on http://rudylab.wustl.edu/
research/cell/methodology/markov/ina.htm). Temperature-
dependence of the transition rates was incorporated using
a Q10 factor approach according to the following equation:
a(T)=Q10
(TT0) / 10Ua(T0), where T is absolute temperature,
a(T) is the rate at temperature T, and a(T0) the original
model rate at the reference temperature T0 of 310.15 -K. To
reconstruct the AP of the right ventricular epicardium, this
INa formulation was introduced into the Luo–Rudy
dynamic (LRd) cell model [14], with the updates proposed
by Faber [15]. As done previously [16], the transient
outward K+ current (Ito) was incorporated according to
Dumaine et al. [17] with a maximal conductance of 1.35mS/AF to simulate the high I to density in the right
ventricular epicardium. The AP was elicited by a 0.5 ms
current pulse of 80 AA/AF.3. Results
3.1. Description of four index cases with fever-sensitive BrS
This study included four male index cases of Caucasian
origin in whom either typical BrS ECG pattern and/or VT
was triggered by fever. Patient 1, 44-year-old, was admitted
in the emergency room for investigation of a first episode
of syncope during fever (up to 39 -C) caused by pneumo-
nia. The ECG was suggestive of BrS (Fig. 1) and an
ajmaline test was positive. No sustained ventricular
arrhythmia was inducible during electrophysiological study
(EPS). The patient received an implantable cardioverter
defibrillator (ICD). Patient 2, 57-year-old, was referred for
investigation of syncope while driving resulting in a car
accident. Resting ECG showed clear ST segment elevation
in V1–V2 compatible with BrS, and an ICD was implanted
(Fig. 1). During three fever episodes due to pneumonia, the
patient had several sustained VT episodes successfully
terminated by the ICD. Patient 3, a 45-year-old subject with
no previous history of syncope, was admitted at the
hospital for bacterial enteritis with fever (39.8 -C). The
routine ECG showed a typical BrS pattern (Fig. 1). Two
days later, when the patient was afebrile, the ECG was
normalized. A flecainide test was positive, but no
ventricular arrhythmia was inducible during EPS. The
clinical presentation of the fourth patient, a 50-year-old
Index Case 1 ECG (38.0oC, pneumonia)
V1
V2
V3
V1
V2
V3
V1
V2
V3
Index Case 2 ECG (rest, no fever)
Index Case 4 ECG (38.1oC, pleuritis)
V1
V2
V3
Index Case 3 ECG (39.8oC, enteritis)
Fig. 1. Electrocardiograms of the four unrelated index cases showing different BrS patterns in leads V1–V3. The index cases 1–3 are patients followed at the
University Hospital of Lausanne (Switzerland). Patient 4 originated from Pilzen (Czech Republic).
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was admitted at the hospital with pleuritis and fever (38.1
-C). The ECG showed downward sloping ST segment
elevations in V1–V3 and was normalized as soon as the
patient was afebrile. However, a similar abnormal ECG was
recorded after infusion of ajmaline. Only patient 3 had a
family history of SCD; his half-brother died suddenly at
age 48 for an unknown reason, with no demonstrable heart
disease.
3.2. Identification of two SCN5A mutations
We screened all coding exons of SCN5A by a PCR-
DHPLC-sequencing approach. A novel heterozygous mis-
sense mutation was identified in patient 2. A T to G
substitution at position 974 resulted in the L325R mutation
with a positively charged arginine (Fig. 2A). The leucine-
325 residue is located in the linker segment preceding the
domain 1 P-loop (Fig. 2C). In patient 3, a heterozygous
non-sense mutation was identified, R535X, resulting from
a C to T substitution at position 1603. This mutation leads
to a premature stop codon (Fig. 2B) and has beenpreviously described [18]. However, an investigation of
the functional consequences of this mutation has not been
performed, yet.
3.3. Electrophysiological characterization of the two mutant
Nav1.5 channels
The functional consequences of the SCN5A mutations
were studied, using HEK293 cells transiently transfected
with mutant cDNAs. As illustrated in Fig. 3A, the level of
expression of the L325R mutant channels analysed by
Western blot was comparable to that of WT channels. In
contrast, using the patch-clamp technique, L325R channels
generated INa that was reduced by about 80%, compared to
WT channels (Fig. 3B–C). At room temperature (22 -C),
the steady-state inactivation parameters of L325R channels
were not different from WT (Table 1). In contrast, the
L325R mutation caused a ¨10 mV positive shift of the V1 / 2
steady-state activation curve (Table 1). Kinetics of activa-
tion (assessed by the time to the peak) and onset of fast
inactivation were slower for the L325R INa (Table 1 and
Fig. 4A).
AW
T
L3
25
R
Co
nt
ro
l
Nav1.5
60
114
81
50
37
26
KDa
WT L325R
0
50
100
150
200
250
300
350
I N
a
pe
ak
cu
rr
e
n
t(
pA
/p
F) ***
1 ms
1 
nA
WT L325R
-100 mV
10 ms
Co
nt
ro
l
W
T
R5
35
X
114
81
WT R535X
I N
a
pe
ak
cu
rr
e
n
t(
pA
/p
F)
***
1 ms
1 
nA
WT R535X
Nav1.5
KDa
Nav1.5
R535X
B
C
-100 mV
10 ms
0
50
100
150
200
250
300
350
D E
F
Fig. 3. Biochemical and functional analysis of L325R and R535X mutant
channels. (A) Western blot of HEK293 cell lysates expressing WT and
L325R channels. Controls are non-transfected cells. (B) Current traces
recorded from cells expressing WT or L325R channels in response to a
series of 10-ms test pulses (inset). (C) Averaged peak currents of cells
expressing WT and L325R channels, n =15 cells from 3 independent
experiments, ***p <0.001. (D) Western blot of cells expressing WT and
R535X mutant proteins. (E) Current traces recorded from cells expressing
WT or R535X channels. (F) Averaged peak currents of cells expressing WT
and R535X channels, n =15 cells from 3 independent experiments,
***p <0.001.
Fig. 2. Genetic analysis of the two index cases with SCN5A mutations. (A
and B) Sequence analysis of SCN5A exons 8 and 12 with base changes
leading to the L325R and R535X mutations in index cases 2 (A) and 3 (B),
respectively. (C) Membrane topology of Nav1.5 and the location of the two
mutations (circles).
D.I. Keller et al. / Cardiovascular Research 67 (2005) 510–519514Transient expression of R535X channels yielded a
truncated protein with a molecular weight which, as
predicted from the sequence, was about one fourth of that
of the WT protein (Fig. 3D). No INa could be recorded from
cells expressing the truncated protein (Fig. 3E–F).
3.4. Effect of temperature on the properties of WT and
L325R channels and on the action potential
In order to get further insight into the mechanisms
underlying the effect of fever, we analysed the effect of
temperature on WT and L325R channels. Data presented in
the Table 1 (and see Methods) illustrates that we achieved
an excellent voltage-clamp control for the recording of INa
at physiological temperatures. Increasing the temperature
significantly accelerated both the activation and inactivation
kinetics of WT and L325R INa (Fig. 4A and Table 1) and, in
agreement with a previous study [19], the resultant peak INa
was increased. The peak WT INa was 16T4% larger at 42 -C
compared to 22 -C; L325R INa was increased by 24T8%.
The steady-state inactivation and activation parameters were
also measured at 37 -C and 42 -C and the difference in
activation V1 / 2 that was observed at room temperature was
still present (Table 1). No significant temperature-depend-
ence of both V1 / 2 and K-slope factor was observed, neither
for activation, nor for inactivation.
How to explain the increase in peak INa paralleling the
increasing temperature? If one assumes that all kineticprocesses governing INa follow an identical sensitivity to
temperature (Q10 factor), one would expect INa to exhibit an
overall accelerated time course without any major change of
its peak. This increase of peak INa could thus be the
consequence of a Q10, which is larger for activation than for
inactivation, leading to a relatively larger acceleration of
activation, compared to inactivation. To test this hypothesis,
we used, in a first step, a Hodgkin–Huxley formalism to
estimate Q10 for activation and inactivation by fitting WT
INa recordings elicited by pulses to 10 mV with the
function INa = gNamaxU(1exp(amt ))3U(exp(aht ))U
(VENa), where am and ah are the rate constants for
activation and inactivation, respectively. Then, the Q10
factors were computed from the slope of the linear
regression of ln(am) and ln(ah) as a function of temperature.
Q10 values of 2.11 (r =0.97) and 1.90 (r =0.99) were
obtained for am and ah, respectively. In a second step, we
WT L325R
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Fig. 4. INa recordings of WT and L325R channels at different temperatures, and mathematical modelling. (A) Representative current traces obtained after
depolarizing HEK293 cells expressing WT or L325R channels at 20 mV (holding potential 100 mV) at different temperatures. (B and C) Reconstruction of
WT INa, using the Clancy–Rudy model under the assumption of an identical Q10 of 2.0 for all transition rates (B) and of a Q10 that is larger for activation rates
compared to inactivation rates (2.15 vs. 1.9, C). The Q10 used are marked on the respective state transition diagrams. The voltage-clamp protocol is the same as
in (A).
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Markovian model of the WT channel [13], in which we
incorporated temperature-dependence using the Q10 formal-
ism. When we assumed Q10 to be identical for all rate
constants (the value of 2.0 was chosen between 2.1 and 1.9),
increasing temperature from 22 to 42 -C resulted only in a
modest peak INa increase of 5.2% (Fig. 4B). In the
simulation presented in Fig. 4C, we incorporated Q10 values
of 2.15 for all three activation transitions and 1.9 for both
inactivation transitions. The absence of a temperature-
dependence of V1 / 2 for steady-state activation and avail-
ability in our experiments indicates that there is no change
in the steady-state occupancy of the different states with
increasing temperature. Consequently, this suggests that for
a given transition, the ratio of the forward and backward
rates does not change with temperature. Therefore, the Q10’s
for the reverse transitions (deactivation and recovery from
inactivation, respectively) were set equal to that of the
forward transitions. The Q10’s for the transition between
states IF and C1 could not be determined from our
experiments and an intermediate value of 2.0 was assumedin both directions. Using this set of Q10 parameters, peak INa
increased by 24.8% when temperature was increased from
22 to 42 -C (Fig. 4C), an increase which is similar to that
observed experimentally. The effects of this temperature-
dependent behaviour of WT INa on the right ventricular
epicardial AP were further investigated using the LRd
model (Fig. 5). In the control simulation (100% INa, 37 -C,
Fig. 5A), the AP exhibited a deep notch characteristic of the
right ventricular AP. No significant changes in AP
morphology were observed when either temperature was
increased to 40 -C (Fig. 5B) or when INa was reduced to
50% to simulate a heterozygote BrS mutant cell (Fig. 5C).
However, with 50% INa and at 40 -C, the AP exhibited
premature repolarization and a loss of the dome, consistent
with the cellular model of BrS (Fig. 5D).
3.5. Rescue of the L325R Nav1.5 currents
The large decrease in peak current density caused by the
L325R mutation (about 80%) cannot be explained by the
alterations in the biophysical properties of L325R Nav1.5.
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Fig. 6. Treatments rescuing L325R channels and dominant negative effect
of L325R channels. (A) HEK293 cells were transfected with WT or L325R
cDNAs and INa was measured after 48 h. L325R cells were treated with
either thapsigargin 1 AM for 12 h, curcumin 25 AM for 24 h, or mexiletine
500 AM for 24 h, or incubated for 24 h at 28 -C; n =15–20 cells from at
least 2 independent experiments, **p <0.01, ***p <0.001 vs. L325R. (B)
HEK293 cells were transfected with WT and mutant cDNAs. 100%
corresponds to 0.3 Ag cDNA per transfection flasks. In the second
condition, the WT cDNA was reduced to 50% (0.15 Ag cDNA) and
complemented with empty cDNA vector. The condition mimicking the
heterozygous expression of WT and mutant channels revealed an
interference of the L325R proteins with the current generated by the WT
channels. The R535X protein had no negative influence on the WT
currents; n =15–20 cells from at least 3 independent experiments,
*p <0.05, **p <0.01. (C) Western blots of HEK293 cell lysates illustrating
the levels of expression of WT and mutant channels in the four conditions
analysed in (B). Protein loading was verified by anti-actin immunoblotting.
Fig. 5. Mathematical modelling of the AP using the temperature-dependent
INa model presented in Fig. 4C. (A) Control AP (at 37 -C and with 100%
INa). (B) Simulation of increased temperature (40 -C, with 100% INa). (C)
Simulation with 50% INa, mimicking a heterozygote genotype, at 37 -C.
(D) Simulation with 50% INa and at 40 -C. Note the abbreviation of the AP
and the loss of the dome.
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positively charged arginine, we considered the hypothesis
that this mutation influences the folding process of the
protein, thus altering either biosynthesis or trafficking of the
channel. Fig. 6A illustrates that, similarly to a recent report
[20], pre-incubation of the cells expressing L325R channels
with 500 AM mexiletine rescued the mutant INa up to 55%
of the WT current. We also investigated the effect of
curcumin, which has been shown to rescue misfolded
mutant CFTR channels in a mouse model of cystic fibrosis
[21]. This drug is a low-toxic sarcoplasmic reticulum Ca2+-
ATPase inhibitor [22]. Incubation with 25 AM of curcumin
during 24 h increased significantly the mutant currents by
¨150% (Fig. 6A). In contrast, thapsigargin, another drug
known to rescue certain misfolded ion channels [23], had no
effect. In addition to these treatments expected to improve
trafficking of misfolded channels, we also incubated cells
expressing L325R channels for 24 h at 28 -C. This
condition also partially rescued the mutant channels by
¨300% (Fig. 6A).
3.6. Dominant negative effect of the L325R mutant allele
Consistent with an autosomal dominant trait, both
SCN5A mutation carriers were found to be heterozygous.
In order to mimic this state in our cellular model, we
investigated the co-expression of WT and mutant ‘‘alleles’’
by co-transfecting WT and mutant cDNAs. Fig. 6B shows
that when reducing the amount of WT cDNA by 50%, the
resultant INa was decreased by about 50%. This condition
represents the clinical situation were there would be no
synthesis at all of the protein resulting from the mutant
allele. However in our experimental model, both mutants
were expressed (Fig. 3A and D). When WT and L325R
channels were co-transfected in a 1 :1 ratio, the peak INa was
reduced to only 18T8% of the control condition where100% of WT channels were expressed (Fig. 6B). This
finding strongly suggests that the L325R allele exerts a
dominant negative effect on WT channels. In contrast, this
negative effect was not observed when the truncated R535X
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the total pool of expressed Nav1.5 proteins is unchanged
(Fig. 6C), it can be postulated that the L325R channels
interfere with the trafficking of WT channels.4. Discussion
In this study, we identified two mutations in the SCN5A
gene in four index patients with BrS pattern ECGs during
episodes of fever. Our in vitro data indicate that the
mutations cause an important loss-of-function of the
Nav1.5 channels. Functional analyses of the L325R and
R535X mutant channels suggest that the manifestations of
fever-exacerbated BrS may not be mutation specific.
Furthermore, our experiments suggest novel molecular
mechanisms underlying BrS, such as misfolding of mutant
proteins leading to dominant negative effect of mutant
channels.
4.1. Clinical and genetic findings
Fever can trigger VT/VF in BrS patients [4]. Here, we
report four male cases in which SCN5A has been screened.
Two mutations were found; R535X in an asymptomatic
patient with a typical BrS ECC pattern during fever and
L325R, a novel mutation, in a patient with fever-induced
VT. The main clinical implications of these findings are that
BrS has to be considered in patients with unexplained
syncope during febrile state, and that genetic investigation
should be performed in patients with an ECG suggestive of
BrS during fever. Finally, BrS patients should be advised to
take antipyretic drugs early in the course of any febrile
illness.
4.2. Possible mechanisms of fever susceptibility in BrS
patients
One of the current models explaining the ECG alterations
seen in BrS is based on an imbalance between the
depolarizing and repolarizing currents during the AP phase
1, mainly in cells expressing a large transient outward Ito
current as the epicardial cells of the right ventricle [1]. In
patients with loss-of-function mutations of Nav1.5, resulting
in less INa during the phase 1, the large Ito current may
repolarize the membrane prematurely producing a loss of
the dome (phase 2) of the AP. When such premature AP
shortening happens heterogeneously in the myocardium,
this may generate phase 2 re-entries that can cause VT/VF.
Hence, the delicate balance of currents, mainly Ito (repola-
rizing), ICa and INa (both depolarizing), during the AP phase
1 is very critical.
How could an increase of temperature above 37 -C alter
this subtle balance in patients? It has been shown that the
T1620M SCN5A mutation found in patients with ‘‘classi-
cal’’ BrS alters the temperature sensitivity of fast inactiva-tion of these channels [17]. However, our study suggests
that in patients carrying a SCN5A mutation at the
heterozygous state in whom the function of mutant
channels is either reduced or abolished, the temperature-
dependent properties of WT INa itself might also lead to the
typical ECG characteristics during fever. This concept is
supported by the observation that the patient with the
R535X mutation (channels yielding no measurable current)
and the patient with the L325R mutation (channels
mediating only a small INa) both exhibited sensitivity to
fever. Moreover, the investigation of the L325R channel
properties at different temperatures was not consistent with
a mutation specific effect of temperature that would lead to
a further decrease of mutant INa. In consequence, we
postulate that the effect of elevated temperature on the
remaining INa, which is mainly or totally mediated by WT
channels, could be responsible for the ECG phenotype in
BrS patients. Fig. 4 illustrates that the effects of increasing
the temperature on WT INa are multiple and intricate,
suggesting that distinct temperature sensitivities govern the
different state transitions of the sodium channel (e.g.,
activation and inactivation). As supported by the simula-
tions presented in Fig. 5, this complex temperature-
dependence of WT INa might then be crucial in determining
the balance of currents during depolarization and during the
phase 1 of the AP. During phase 1, most of INa has
undergone fast inactivation and only a small fraction of INa
is still contributing to depolarization. Although small, our
simulations indicate that this fraction is nonetheless critical.
Therefore, accelerated inactivation under conditions of
elevated temperature, combined with a decreased level of
expression of Nav1.5 channels, might then be sufficient to
obliterate the ‘‘phase 1 depolarization reserve’’ and to shift
the delicate balance of currents in favour of a premature
repolarization, thus revealing a BrS phenotype. This
hypothesis is supported by a recent model study by Gima
and Rudy who demonstrated that the accelerated inactiva-
tion of the T1620M Nav1.5 channel leads to a BrS ECG
phenotype through a decreased INa [16]. However, since
the differences in WT INa properties measured at 37 and 42
-C were minimal (Table 1), one should be cautious in
extrapolating our experimental data to the situation of BrS
patients with fever. Furthermore, the influence of elevated
temperature on the AP is complex and the role of fever in
BrS is likely to be multifactorial. It is plausible that
temperature-dependent changes of currents other than INa
could precipitate the BrS during fever. For example, fever
may also increase the peak transient outward current (Ito)
through mechanisms similar to those we propose for INa
and precipitate repolarization in epicardial tissue. It was
beyond the scope of this study to introduce temperature-
dependent kinetics for currents other than INa and we are
aware that this represents a limitation of the model;
however, it allows us to demonstrate that the mechanism
we propose may be a realistic option that remains to be
explored further.
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phenotype
The consequences of the BrS SCN5A mutations on
Nav1.5 function are multiple [1]. Recently, Chahine’s group
reported three BrS SCN5A missense mutations leading to a
charge modification and generating channels that were not
trafficked to the membrane [24–26]. The L325R mutation
described here leads to a similar phenotype since the
protein expression was not altered (Fig. 3A) and treatments
with chemical chaperones, as well as expression at 28 -C,
partially rescued INa. Misfolding of Nav1.5 therefore
appears to be one of the mechanisms underlying BrS, as
it is the case for KvLQT1 and hERG channels in congenital
long QT syndrome [27], and CFTR channels in cystic
fibrosis [21]. The significant mutant INa increase obtained
by treating the cells with curcumin may be of clinical
importance since this drug has a very low toxicity profile
and has already been tested in a clinical setting as an anti-
cancer drug [28]. In contrast, thapsigargin, which similarly
to curcumin can block the endoplasmic reticulum Ca2+-
pump, did not rescue the mutant INa. It may therefore be
possible that the positive effect of thapsigargin is restricted
for specific channels [23].
4.4. Dominant negative effect of mutant Nav1.5
A dominant negative effect of mutant ion channel
subunits has been frequently reported for channels formed
by multiple a-subunits, such as the KvLQT1 channel in
LQTS [29]. In contrast, Nav1.5 is not known to oligomerize
with other a-subunits in order to form a minimal ion
channel, and, therefore, the dominant negative effect of
L325R channels on WT Nav1.5 (Fig. 6B) was unexpected. It
can be postulated that mutant proteins interfere directly or
indirectly with either biosynthesis or trafficking of WT
channels. It also remains to be shown whether this
mechanism could be generalized to other mistrafficked
BrS channels since, to our knowledge, no study directly
addressed this issue.5. Conclusions
In the past few years, a number of case reports described
that fever triggers the clinical manifestations of BrS. Hence,
based on these studies and the present work, BrS should be
considered in any patient with syncope during febrile state.
The genetic background of BrS is heterogeneous. In the
small population of fever-susceptible cases presented here,
two patients out of four did not carry any mutation in
SCN5A. Additional investigations are therefore needed to
identify the genetic bases of this disorder. Finally, as
illustrated by our findings, the molecular and cellular
mechanisms underlying the fever-dependent manifestations
of BrS are complex. Further studies are needed in order toelucidate this important issue since there is no curative
treatment available for BrS to date.Acknowledgments
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